EDGEWISE THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSat, 04 Apr 2026 05:39:09 +0200https://images.finanzen.net/images/finanzen_net_neu.gifEDGEWISE THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netEdgewise Therapeutics stellte Zahlen zum jüngsten Quartal vorSun, 01 Mar 2026 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-stellte-zahlen-zum-juengsten-quartal-vor-15525949Edgewise Therapeutics hat am 26.02.2026 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 31.12.2025 – vorgestellt.Es wurde ein Verlust je Aktie in Höhe von 0,47 USD ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-stellte-zahlen-zum-juengsten-quartal-vor-15525949BioNTech-Aktie nicht dabei: Auf diese Top-Biotech-Aktien setzen Analysten für 2026Tue, 10 Feb 2026 23:20:00 +0100https://www.finanzen.net/nachricht/aktien/katalysatoren-voraus-biontech-aktie-nicht-dabei-auf-diese-top-biotech-aktien-setzen-analysten-fuer-2026-15464922• Experten von Truist Securities und Piper Sandler nennen jeweils Favoriten für 2026 bei Biotech-Aktien
• Zwei Unternehmen schaffen es auf beide Listen
• ...

]]>https://www.finanzen.net/nachricht/aktien/katalysatoren-voraus-biontech-aktie-nicht-dabei-auf-diese-top-biotech-aktien-setzen-analysten-fuer-2026-15464922DAX beendet Handel knapp im Minus -- US-Börsen uneinheitlich -- ON Semi: Gewinneinbruch -- TUI bestätigt Ausblick -- Apple, Novo Nordisk, Goodyear, SAP, BASF, BYD, DroneShield, Alphabet, TSMC im FokusTue, 10 Feb 2026 06:53:09 +0100https://www.finanzen.net/nachricht/aktien/heute-im-fokus-10-02-2026-15476326
Am deutschen Aktienmarkt hielten sich die Anleger am Dienstag zurück.

So eröffnete der DAX mit einem kleinen Minus, konnte sich anschließend aber ...

]]>https://www.finanzen.net/nachricht/aktien/heute-im-fokus-10-02-2026-15476326Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026Tue, 06 Jan 2026 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-13-2026-15395201

BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-13-2026-15395201Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesMon, 05 Jan 2026 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15392280

BOULDER, Colo., Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15392280Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic CardiomyopathyWed, 24 Dec 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-15378610

– In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-15378610Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesTue, 02 Dec 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15328000

BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15328000Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of DirectorsThu, 20 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-15295352

BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-15295352Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesWed, 12 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15266783

BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-15266783Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael CarruthersMon, 10 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-announces-appointment-of-michael-nofi-as-chief-financial-officer-and-the-retirement-of-current-cfo-r-michael-carruthers-15249798

BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle ...

]]>https://www.finanzen.net/nachricht/aktien/edgewise-therapeutics-announces-appointment-of-michael-nofi-as-chief-financial-officer-and-the-retirement-of-current-cfo-r-michael-carruthers-15249798